BRAF and melanoma: Melanoma patients harbor BRAF mutations in 40%‐60% resulting in constitutive activation of prosurvival signaling through the MAPK pathway.1 Targeted therapies against BRAF have shown promising results and a profound effect with 80% overall response rate in melanoma patients harboring the BRAFV600E mutation.